LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells
Authors:
Open Access
- 13 March 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1332922
Abstract
LTX-315 is a synthetic cationic oncolytic peptide with potent anticancer activity but limited toxicity for non-malignant cells. LTX-315 induces both immunogenic tumor cell death and generation of tumor-specific immune responses in multiple experimental tumor models. Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity. We found that LTX-315 treatment induces the maturation of DCs, both indirectly through the release of cancer cell-derived damage-associated molecular patterns (DAMPs)/alarmins and nucleic acids (DNA and RNA) capable of triggering distinct Toll-like receptor (TLR) signaling, and, directly by activating TLR7. The latter results in the ignition of multiple intracellular signaling pathways that promotes DC maturation, including NF-κB, mitogen activated protein kinases (MAPKs), and inflammasome signaling, as well as increased type 1 interferon production. Critically, the effects of LTX-315 on DCs the consequent promotion of anti-melanoma immunity depend on the cytosolic signal transducer myeloid differentiation response gene 88 (MyD88). These results cast light on the mechanisms by which LTX-315 induces DC maturation and hence elicits anticancer immunity, with important implications for the use of LTX-315 as an anticancer immunotherapeutic.Keywords
This publication has 47 references indexed in Scilit:
- Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic PeptidesTrends in Cancer, 2021
- Plasmacytoid dendritic cell in immunity and cancerJournal of Neuroimmunology, 2018
- Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospectsCellular and Molecular Life Sciences, 2017
- Dendritic Cells and Cancer ImmunityTrends in Immunology, 2016
- Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide2016
- Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315Cancer Immunology, Immunotherapy, 2014
- Dendritic-Cell-Based Therapeutic Cancer VaccinesImmunity, 2013
- The expanding scope of antimicrobial peptide structures and their modes of actionTrends in Biotechnology, 2011
- The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generationCellular Immunology, 2011
- Antigen-Presentation Properties of Plasmacytoid Dendritic CellsImmunity, 2008